Management

Mr. Bruno is CEO, Technical Officer, founding shareholder, Board of Directors member since 2010, full member of the Brazilian Society of Clinical Oncology, member of the American Society of Clinical Oncology (ASCO), full member of the ASCO Clinical Practice Guidelines Committee and board member of the International Network for Cancer Research and Treatment – ​​INCTR (Brazilian branch). He is an oncologist with a degree from the Federal University of Minas Gerais and a postgraduate degree in Clinical Oncology from MD Anderson Cancer Center, University of Texas, Houston.

Mr. Rodrigo is the Company’s Executive Vice Presidente. Prior to that, he was CEO in Brazil of IHS Towers (successor of Cell Site Solutions and previously controlled by Goldman Sachs), a company that develops built-to-suit telecommunications infrastructure solutions and served as CFO of Rossi Residencial and of Elektro Eletricidade e Serviços SA, and Investor Relations Officer at Ashmore Energy International, based in Houston, TX, with more than 20 years’ experience in management positions in the telecommunications, energy, construction, real estate and infrastructure sectors. He is also advisor to the Board of Directors of ARG Realty Group, in Argentina. He holds a degree in civil engineering (Summa Cum Laude) from the Federal University of Rio de Janeiro and an Executive MBA from Insper, in São Paulo.

Mr. Cristiano Camargo has more than 20 years of experience in investment banking and private equity, including 14 years at Goldman Sachs, where he was most recently a Managing Director in their private equity arm overseeing growth and corporate equity investments in Brazil and Latin America. He was previously a board member of Oncoclínicas from 2015 to 2021, during which time he led or was involved in its capital raising activities, in addition to helping with the Company’s strategic planning and business development activities. Mr. Camargo left Goldman Sachs and joined Oncoclinicas as a senior executive responsible for the Company’s Strategy and Investor Relations in November 2021. He currently holds the positions of Financial, Strategy and Investor Relations Officer.

Ms. Cinthia was the General Counsel for pharmaceutical Sanofi for eight years and for publicly traded energy company Elektro for five years. Ms. Cinthia was included in lists of the best legal executives in Brazil and Latin America. He has an international executive MBA (USP/EM-Lyon/Cambridge) and graduate and post-MBA at Saint Paul University (Brazil). He has experience in the infrastructure sector having worked at Alston as responsible for turnkey contracts and O&M contracts in Brazil and Latin America and is a member of the Board of Directors of Tienda Inglesa.

Mr. Eduardo is a professional with more than 25 years in the health area, 19 of them dedicated to the pharmaceutical industry (16 years in the Swiss company A F. Hoffmann – La Roche, 13 of which occupying leadership positions in the Specialty Care segment in Oncology and Hematology). He is currently responsible for the Company’s institutional relationships, primarily with partner pharmaceutical companies and physicians.

Mr. Giovane holds a degree in law and a postgraduate degree in management development from ISE / IESE – Instituto Superior de Empresa / Accord University of Navarra, Spain. He has 25 years of experience in Human Resources executive leadership aligned with the business and career developed in large national and multinational companies in the telecommunications, retail and services segment, such as Tim, Telefonica, Walmart and Sonae.

Mr. André is a physician and recently joined Oncoclinicas. Prior to that, he worked at GNDI and Americas / United Health Group and health specialist McKinsey & Company Latam.

Mr. Mathias is a pharmacist, post-graduated in business administration, holds an MBA in business management at FGV and has developed a 15-year career essentially in retail in large drugstore chains. In 2010, invited to be part of the Company’s professionalization and expansion plan, he joined the company, where he developed excellent projects focused on management and results that culminated in his promotion to the Operations Department.

Mr. Santoro has a degree in Mathematics from Centro Universitário Fundação Santo André, an MBA in Business Administration from Fundação Getúlio Vargas – FGV and an MBA in Health Information Technology Management from Unifesp – Universidade Federal de São Paulo. Before joining Oncoclínicas, Mr. Santoro worked at Hospital Israelita Albert Einstein for 8 years, where he led mainly the Hospital’s digital transformation project.

Mr. Carlos Gil is a thoracic oncologist and PhD from the Free University of Amsterdam. He serves as President of the Oncoclínicas Institute and has experience in the Research Coordination of the National Cancer Institute (INCA), Coordination of the National Network for the Development of Anticancer Drugs (REDEFAC/Ministry of Health, at ANVISA, as a member of the Scientific Committee, and as a member of the International Affairs Committee of the AACR – American Association for Cancer Research, Member of the Career Development and Fellowship Committee and of the Bylaws Committee of the International Association for the Research and Treatment of Lung Cancer (IASLC), Board Member in Brazil of the International Network for Cancer Treatment and Research (INCTR) Board Member of the Americas Health Foundation (AHF) Winner of the American Society of Clinical Oncology (ASCO) Partners in Progress Award.

Marcos holds a degree in Electronic Engineering from FEI/SP and a postgraduate degree in Marketing from ESPM/SP and in Health Administration from INSPER. He has long experience in the healthcare sector in Brazil and Latin America, having worked at Philips Healthcare (1998-2013), Johnson&Johnson (2014-2017), Ortho Clinical Diagnostics (2017) and AC Camargo Cancer Center (2018-2021)

Services marketing strategist, graduated in Advertising and Marketing, with an MBA at Fundação Getúlio Vargas and specializations at Pennsylvania University, Copenhagen Business School, IE Business School, Rotterdam School of Management. Consolidated career in national and multinational companies, helping brand positioning challenges and connecting companies to solutions that operate in synchrony with new business contexts, operational competences and innovative strategic directions.

Mr. David is Managing Director and Head of Latin America Corporate and Growth Equity Investment of Merchant Banking at Goldman Sachs, was Chairman of the Board of Cell Site Solutions, is Chairman of the Board of Directors of Tienda Inglesa US Holdings LLC and a member of the Board of Directors of Paige.AI, Inc and Olist. In the academic area, he has a degree in History and Economics from Brown University (B.A.), in Law from Stanford Law School (J.D.) and an MBA from the Stanford Graduate School of Business.

Mr. Bruno is CEO, Technical Officer, founding shareholder, Board of Directors member since 2010, full member of the Brazilian Society of Clinical Oncology, member of the American Society of Clinical Oncology (ASCO), full member of the ASCO Clinical Practice Guidelines Committee and board member of the International Network for Cancer Research and Treatment – ​​INCTR (Brazilian branch). He is an oncologist with a degree from the Federal University of Minas Gerais and a postgraduate degree in Clinical Oncology from MD Anderson Cancer Center, University of Texas, Houston.

Mr. Allen Gibson is the Chief Investment Officer of Centaurus Capital LP and Chief Investment Officer of the Laura and John Arnold Foundation. Prior to joining Centaurus Capital, Allen was senior vice president of institutional asset management at Royal Bank of Canada. He is a member of the Board of Directors of Albertsons Companies Inc. In addition, he holds a BA in Political Science from Emory University and an MS in Philosophy from Boston College.

Ms. Clarissa works as a clinical oncologist at the Bahia Oncology Center (NOB), a company controlled by the Company. She holds a bachelor’s degree and a doctorate in medicine from the Federal University of Bahia, with a medical residency at the Medical College of Pennsylvania and the University of Pennsylvania. She is an effective member and President of the SBOC – Brazilian Society of Oncology, member of the board of the International Association for Lung Cancer Study and is the current Chair of the International Committee of the American Society of Oncology. She works as lead physician at the Oncology Center at Hospital Santa Izabel (Bahia).

Mr. João is Vice President at Goldman Sachs and was a member of the Board of Directors of Tienda Inglesa. He has a degree in business administration from IBMEC São Paulo (Insper).

Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He currently holds the position of Director of the Yale Cancer Center and Chief Physician at Smilow Cancer Hospital at Yale New Haven. From 1997 to 2021, she was Head of the Breast Oncology Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. As of 2013, he has held various institutional roles at Dana-Farber, most recently as Head of Clinical Development. He was the Thompson Chair in Breast Cancer Research and Professor of Medicine at Harvard Medical School. He is currently the president-elect of the American Society of Clinical Oncology.

Mr. Jorge holds a double degree in medicine from the University of Porto (Portugal) and the Federal University of Paraná. He holds a Ph.D. in Molecular Pathology of Breast Cancer from the Institute of Cancer Research/Royal Marsden Hospital, London, and was appointed Team Leader of the Molecular Pathology Laboratory in 2016. In 2010, he became the Full Professor of Molecular Pathology at the Institute of Cancer Research/Royal Marsden Hospital. He is Director of Experimental Pathology in the Department of Pathology and an affiliate member of the Human Oncology and Pathogenesis Program at the Memorial Sloan Kettering Cancer Center in New York. He has published over 530 peer-reviewed articles and received awards such as the CL Oakley Lectureship (Pathological Society of Great Britain and Ireland), the BACR Translational Research Award, the Ramzi Cotran Young Investigator Award (United States and Canadian Academy of Pathology) and the Future Leaders Prize ( Cancer Research UK). It has developed new methods for sequencing individual cells (single cell sequencing) and for analyzing DNA obtained by liquid biopsies, which have been adopted for monitoring and identifying breast cancer, as well as for determining mechanisms of resistance to treatments.

Ms. Flavia has a degree in Chemical Engineering from the Federal University of Rio de Janeiro, an Executive MBA from Fundação Dom Cabral and other certificates from the London Business School and INSEAD. Flavia has extensive professional experience in national and multinational companies and in different sectors, such as 8 years in Banking, 10 years in Telecommunications and 6 years in Retail. Since May 2019, Flavia has been President of Adidas do Brasil. Flavia also has extensive experience in boards of directors, having served as an Independent Advisor at Lojas Marisa between 2018 and 2019, as an independent member of the Board of Directors of TIM Participações SA, since June 2019, and as an independent member of the Board of Directors of BRF SA , since April 2020.

Ms. Flavia has a degree in Chemical Engineering from the Federal University of Rio de Janeiro, an Executive MBA from Fundação Dom Cabral and other certificates from the London Business School and INSEAD. Flavia has extensive professional experience in national and multinational companies and in different sectors, such as 8 years in Banking, 10 years in Telecommunications and 6 years in Retail. Since May 2019, Flavia has been President of Adidas do Brasil. Flavia also has extensive experience in boards of directors, having served as an Independent Advisor at Lojas Marisa between 2018 and 2019, as an independent member of the Board of Directors of TIM Participações SA, since June 2019, and as an independent member of the Board of Directors of BRF SA , since April 2020.

Ms. Carla holds a bachelor’s degree in Computer Science from Universidade Estadual Paulista – UNESP and in Accounting from Pontifical Catholic University of Minas Gerais – PUC Minas. He worked in an independent audit at Arthur Andersen, Deloitte and EY between 1996 and 2010 and was an internal audit manager at Confab, a publicly-held Brazilian company controlled by the Italian-Argentine group Techint/Tenaris. She was a partner at Hirashima & Associados, where she led accounting and financial consulting services in corporate reorganizations and acted as a consultant at the Accounting, Actuarial and Financial Research Foundation – FIPECAFI. From July 2014 to August 2017, he held the position of controller in electricity generation companies. He was chairman of the Audit Committee of Caixa Econômica Federal and is currently a member of the board of directors of BRB – Banco de Brasília and of fiscal councils and audit committees of publicly-held and privately-held companies.

Mr. Felipe has a degree in mechanical engineering from UFRJ, a postgraduate degree in finance from the IAG at PUC-Rio and a strictu-senso master’s degree in business management from EBAPE at FGV-Rio. He attended the Advanced Management Program, offered by the Institut Européen d’Administration des Affaires (INSEAD) and Fundação Dom Cabral in 2011, attended the Mergers and Acquisitions course at FGV-SP in 2013 and participated in the Technical Journey to Silicon Valley at the IBGC , in August 2018. He has experience in executive positions in private multinational companies, notably at North American Harsco Metals, where he was Vice President for South America, until January 2013, and at Marte Engenharia, a company of the Canadian group SNC Lavalin, where he served as General Director of the electricity unit in Brazil, until December 2014. He is a Certified Board Member by the Brazilian Institute of Corporate Governance-IBGC since 2017, completed the IBGC Board of Directors Training course in 2013 and is currently member of the Audit Committee of INB – Indústria Nucleares do Brasil since 2019.

Mr. Marcelo del Vigna is a lawyer with 18 years of experience. Postgraduate in Strategic Management and Master in Private International Law. He is currently the legal vice president of Globenet Cabos Submarine and is an effective member of the fiscal council of the Companies.

Professional with over 25 years of experience in the areas of inspection and control and current Fiscal Council member and member of the Statutory Audit Committee of several organizations. As Director, he restructured or implemented the areas of Internal Audit, Internal Control, Risk Management and Compliance in multinationals. He has experience in implementing Audit Committees in privately held, publicly traded, state-owned, private and B3 listed companies. Member of Statutory Audit Committee in retail, financial, technology, logistics, research and education companies. In the committees, it helped to strengthen governance and maturity of risk management, internal control, internal audit and compliance programs. Financial, Training and Events Director (Pro bono) of the Institute of Internal Auditors – IIA Brasil from 01/2015 to 02/20. Master in business controllership, with specializations in business strategy and organizational consulting. He works as a professor at IBGC in the courses for Board Members and in company. Additionally, he has the IBGC certifications: CCA, board member; CCF, tax advisor; CCoAud+, Experienced Audit Committee Member and CCSA for The IIA Global. He has several publications in the areas of inspection and control.

Marcus Vinicius Dias Severini was graduated in Accounting and Electrical Engineering in Brazil. Holds more than 30 years of experience in controller. Currently, is a audit commitee member of the Audito of OCeanPact Serviços Marítimos S.A, and Fundação Vale do Rio Doce de Seguridade Social – Valia. He is a Fiscal Council member of Vale S.A.